Formulation and Specifications: Tablets: 5 mg
Indications: For the treatment of disease-related splenomegaly or disease-related symptoms in adult patients with intermediate-risk or high-risk primary myelofibrosis (also known as chronic idiopathic myelofibrosis), myelofibrosis secondary to true erythroblastosis, or myelofibrosis secondary to primary thrombocytosis.
Key points for rational drug use.
1. Therapeutic dose: Give starting dose according to platelet counts. (1) Platelet count in the range of (100-200)×109/L, starting dose is 15 mg twice daily. (2) For platelet counts >200×109/L, the starting dose is 20 mg twice daily. (3) Platelet count of (50-100)×109/L, the starting dose is 5 mg twice daily.
2. This product may cause hematologic adverse reactions, including thrombocytopenia, anemia, and neutropenia. Prior to treatment, a complete blood count must be performed, followed by weekly monitoring, and after 4 weeks, monitoring may be performed every 2 to 4 weeks until stability is achieved, and then monitoring may be performed as clinically indicated. When thrombocytopenia or anemia occurs, the dose may be reduced or the drug may be temporarily discontinued and platelets or red blood cells may be transfused if necessary.
3. Symptoms of myelofibrosis may reappear after approximately one week following interruption or discontinuation of treatment with this product. A gradual reduction in the dose of this drug should be considered if urgent termination of treatment is not necessary.
4. The total daily dose should be reduced by approximately 50% when this product is used in combination with a potent CYP3A4 inhibitor or a dual inhibitor of CYP2C9 and CYP3A4 enzymes.